CME/CE Information

Biomarker Testing in Non-Small Cell Lung Cancer Diagnosis

October 16, 2026 – October 16, 2027

This activity is jointly provided by Global Education Group (Global) and GO2 for Lung Cancer.

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

The primary audience for this project is multidisciplinary healthcare professionals (HCPs) involved in the diagnosis, treatment, and longitudinal care of patients with advanced mNSCLC, including those with HER2 (ERBB2)-mutations. This includes medical oncologists, nurse practitioners, physician assistants, oncology pharmacists, molecular pathologists, oncology nurses and navigators, and other team members integral to diagnosis, biomarker testing, treatment selection, and toxicity management, especially those practicing in community, under-resourced, and rural settings, where disparities in access to biomarker testing and targeted therapies remain most pronounced. 

Statement of Need/Program Overview

This activity explores the evolving role of comprehensive next-generation sequencing (NGS) testing in non-small cell lung cancer (NSCLC), highlighting key considerations for selecting appropriate biomarker testing strategies and interpreting results in clinical practice. Participants will examine the differences between single-gene and broad-panel testing approaches and gain insight into the clinical value of early detection of HER2 (ERBB2) mutations. 

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the role of comprehensive NGS testing at diagnosis, progression, and recurrence
  • Differentiate between single-gene and broad-panel biomarker testing strategies
  • Evaluate the clinical implications of early detection of HER2 (ERBB2)-mutant NSCLC through NGS testing
  • Discuss the first-line biomarker-directed treatment landscape for HER2-mutant NSCLC, including current guidelines and ongoing clinical trials


Faculty

Parth Desai

Assistant Professor

Fox Chase Cancer Center


Program Agenda

30-minute online activity

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Global Education Group and GO2 for Lung Cancer. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Contact Hours Designation

Global Education Group designates this continuing education activity for 0.5 contact hour(s) including 0.0 pharmacotherapeutic contact hour(s). 

Disclosures of Relevant Financial Relationships

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by Joint Accreditation and all other accrediting bodies, as applicable, stating those activities where CE credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited CE program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months.  All financial relationships reported are appropriately identified as relevant by Global. All relevant financial relationships have been mitigated in advance of delivery of the activity to learners.

Global Contact Information

For information about the Joint Accreditation (ACCME, ANCC) of this activity, please contact Global at 303-395-1782 or [email protected].